Canopy Growth Corporation · TSX:WEED
Canopy Growth — Investor Presentation (June 2026)
23 slides from Canopy Growth's investor presentation, June 2026
Slide 1: Investor Presentation June 2026
INVESTOR PRESENTATION June 2026
Slide 2: Disclaimers and Cautionary Statements: Forward-Looking Information (1/4)
DISCLAIMERS AND CAUTIONARY STATEMENTS Forward-Looking Information (1/4) Unless otherwise noted or the context indicates otherwise, references in this presentation (this “Presentation”) to the “Company,” “Canopy Growth,” “we,” “us” and “our” refer to Canopy Growth Corporation and its direct and indir
Slide 3: Disclaimers and Cautionary Statements: Forward-Looking Information (2/4)
DISCLAIMERS AND CAUTIONARY STATEMENTS Forward-Looking Information (2/4) our ability to execute on our strategy and the anticipated benefits of such strategy; the ongoing impact of the legalization of additional cannabis product types and forms for adult-use in Canada, including federal, provincial,
Slide 4: Disclaimers and Cautionary Statements: Forward-Looking Information (3/4)
DISCLAIMERS AND CAUTIONARY STATEMENTS Forward-Looking Information (3/4) By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclus
Slide 5: Disclaimers and Cautionary Statements: Forward-Looking Information (4/4)
DISCLAIMERS AND CAUTIONARY STATEMENTS Forward-Looking Information (4/4) Forward-looking statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position and cash flows as of and for periods ended on certain dates and to present informati
Slide 6: Canopy Growth: Positioned for sustainable cannabis market leadership
Canopy Growth: Positioned for sustainable cannabis market leadership Cannabis centered Dedicated to unleashing the power of cannabis in key markets. Brand & Consumer-led Industry-leading brands and products rooted in consumer preferences. Global reach A $70B+ CAD market opportunity by 20281. Improvi
Slide 7: Executing with Discipline Across Each Business
Dedicated to being a leader in the cannabis sector: Executing with Discipline Across Each Business Canada Medical Canada Adult-Use International Storz & Bickel GER, POL, AUS Objectives Canada Medical Cannabis Profitable Scale in International Cannabis Uncontested Leadership Leadership Canada Adult-Us
Slide 8: FY2026 highlights
FY2026 highlights 1. Returned to growth in Canada adult-use cannabis: net revenue +20% YoY. 2. Continued growth in Canada medical cannabis: net revenue +18% YoY. 3. Ended the year with two quarters of sequential growth in International markets cannabis, including net revenue +68% YoY in Q4 FY2026. 4
Slide 9: MTL Cannabis Acquisition Strengthens Competitive and Financial Position
MTL Cannabis ACQUISITION STRENGTHENS COMPETITIVE and financial position • Establishes Canopy Growth as Canada’s largest medical cannabis provider by revenue. • Deepens Québec presence with portfolio of leading brands and two cultivation facilities. • Enhances high-quality flower supply for Canadian
Slide 10: Focus in FY2027: Driving Growth Through Execution and Discipline
FOCUS IN FY2027: Driving Growth Through Execution and Discipline 1. Focus on the markets and categories where we see the strongest opportunities for profitable growth. 2. Build on position as Canada’s #1 medical cannabis provider by revenue. 3. Complete the integration of MTL Cannabis to drive growt
Slide 11: Q4 & Fiscal Year 2026 Financial Results
Q4 & FISCAL YEAR 2026 FINANCIAL RESULTS 11
Slide 12: Cannabis – Q4 FY2026
CANNABIS – Q4 FY2026 • Cannabis net revenue was $54.5M in the fourth quarter ended March 31, 2026 (“Q4 FY2026”), representing an increase of 20% versus the fourth quarter ended March 31, 2025 (“Q4 FY2025”). • Canada medical cannabis net revenue in Q4 FY2026 was $25.3M, representing an increase of 27
Slide 13: Storz & Bickel – Q4 FY2026
STORZ & BICKEL ® – Q4 FY2026 • Storz & Bickel net revenue in Q4 FY2026 was $16.8M, representing a decrease of 14% compared to Q4 FY2025. Softness was attributable to lapping strong sales in the prior year and continued consumer economic uncertainty, offset by strong sales of the recently launched VE
Slide 14: Gross Margin Performance – Q4 FY2026
GROSS MARGIN PERFORMANCE – Q4 FY2026 Drivers of Q4 FY2026 Gross Margin Year-over-Year Change By Adjusted Gross Margin Performance Reportable Segment Consolidated Gross (+) The year-over-year increase in the adjusted gross margin Margin (Adjusted)1 percentage was primarily attributable to improved st
Slide 15: FY2026 Key Financial Highlights
FY2026 KEY FINANCIAL HIGHLIGHTS Canopy Growth delivered Consolidated Net Revenue of $284.6M in FY2026, an increase of 6% from FY2025. vs. (CDN in millions) FY2026 FY2025 Main drivers of revenue growth were: Net Revenue $284.6 6% Cannabis net revenue increased 15% compared to FY2025 driven by growt
Slide 16: Revenue Performance by Channel
REVENUE PERFORMANCE BY CHANNEL1 (in thousands of Canadian dollars, unaudited) FY2026 FY2025 Change Cannabis Canada adult-use cannabis 2 $94,472 $78,828 20% Canada medical cannabis3 $90,818 $77,032 18% $28,654 $30,866 (7)% International markets cannabis4 $213,944 $186,726 15% Storz & Bickel $70,659 $
Slide 17: Appendix: Non-GAAP Measures
APPENDIX: NON-GAAP MEASURES 17
Slide 18: Non-GAAP Measures
NON-GAAP MEASURES Adjusted EBITDA is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Management believes Adjusted EBITDA is a useful measure for investors because it provides meaningful and useful fina
Slide 19: Consolidated Adjusted Gross Margin (Non-GAAP) Reconciliation
CONSOLIDATED ADJUSTED GROSS MARGIN1 (NON-GAAP) RECONCILIATION Three months ended March 31, (in thousands of Canadian dollars except where indicated; unaudited) 2026 2025 Net revenue $ 71,245 $ 65,031 Gross margin, as reported 8,261 10,544 Gross margin percentage, as reported 12 % 16 % Adjustments to
Slide 20: Adjusted Gross Margin by Segment (Non-GAAP) Reconciliation
ADJUSTED GROSS MARGIN1 BY SEGMENT (NON-GAAP) RECONCILIATION Three months ended March 31, (in thousands of Canadian dollars except where indicated; unaudited) 2026 2025 Cannabis segment Net revenue $ 54,463 $ 45,508 Gross margin, as reported 3,652 3,467 Gross margin percentage, as reported 7% 8% Adju
Slide 21: Adjusted EBITDA (Non-GAAP) Reconciliation
ADJUSTED EBITDA1 (NON-GAAP) RECONCILIATION Years ended March 31, (in thousands of Canadian dollars, unaudited) 2026 2025 (As Restated) Net loss from continuing operations $ (262,908 ) $ (514,901 ) Income tax expense 23 7,141 Other (income) expense, net 101,226 390,617 Share-based compensation 4,266
Slide 22: Free Cash Flow (Non-GAAP) Reconciliation
FREE CASH FLOW1 (NON-GAAP) RECONCILIATION Year ended March 31, (in thousands of Canadian dollars, unaudited) 2026 2025 Net cash used in operating activities - continuing operations $ (63,806 ) $ (165,750 ) Purchases of and deposits on property, plant and equipment - continuing operations (5,333 ) (1
Slide 23: Thank You
THANK YOU 23